Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 47 of 47 publications.

Barrett AM, Olayinka-Amao O, Martin S, Doshi D, Bishop KM, Youakim JM. Assessing experiences with trofinetide for rett syndrome: interviews with caregivers of participants in clinical trials. Clin Ther. 2025 Mar;47(3):181-8. doi: 10.1016/j.clinthera.2024.12.012

DiBenedetti D, Neme D, Pan-Petesch B, Willemze A, Wynn T, Kragh N, Wilson A. Patient experience with efanesoctocog alfa for severe hemophilia A: results from the XTEND-1 phase 3 clinical study exit interviews. Clin Ther. 2024 Dec;46(12):1016-23. doi: 10.1016/j.clinthera.2024.09.010

Meyers J, Hoog M, Mody R, Yu M, Davis K. The health care resource utilization and costs among patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors an analysis of a US health insurance database. Clin Ther. 2021 Nov;43(11):1827-42. doi: 10.1016/j.clinthera.2021.09.003

Ardeshirrouhanifard S, An H, Goyal RK, Raji M, Segal J, Alexander GC, Mehta HB. Initiation and switching of direct oral anticoagulants among Medicare beneficiaries with cancer and atrial fibrillation. Poster presented at the 2021 American Heart Association, Epidemiology Scientific Session; May 2021. [abstract] Circulation. 2021 May 25; 143(Suppl 1):AP148.

Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights into patients' experience with Type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019 Nov;41(11):2219-2230. doi: 10.1016/j.clinthera.2019.09.003

Meyers J, Sinha A, Samant S, Candrilli S. The economic burden of congenital cytomegalovirus disease in the first year of life: a retrospective analysis of health insurance claims data in the United States. Clin Ther. 2019 Jun;41(6):1040-1056. doi: 10.1016/j.clinthera.2019.04.022

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. In reply: Network meta-analyses are not about a single treatment but about sets of regimens. Clin Ther. 2019 Jan;41(1):188-90. doi: 10.1016/j.clinthera.2018.11.011

Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E. Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther. 2018 Mar;40(3):480-94. doi: 10.1016/j.clinthera.2018.01.014

Pontes C, Marsal JR, Elorza JM, Aragon M, Prieto-Alhambra D, Morros R. Analgesic use and risk for acute coronary events in patients with osteoarthritis: a population-based, nested case-control study. Clin Ther. 2018 Feb;40(2):270-83. doi: 10.1016/j.clinthera.2017.12.011

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013

Abdul-Jawad Altisent O, Puri R, Regueiro A, Chamandi C, Rodriguez-Gabella T, Del Trigo M, Campelo-Parada F, Couture T, Marsal JR, Cote M, Paradis JM, DeLarochellière R, Doyle D, Mohammadi S, Dumont E, Rodes-Cabau J. Predictors and association with clinical outcomes of the changes in exercise capacity after transcatheter aortic valve replacement. Circulation. 2017 Aug 15;136(7):632-43. doi: 10.1161/CIRCULATIONAHA.116.026349

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012

Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health status of patients with moderate to severe COPD after treatment with nebulized arformoterol tartrate or placebo for 1 year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

Bailey RA, Schwab P, Xu Y, Pasquale M, Renda A. Glycemic control outcomes after Canagliflozin initiation: observations in a Medicare and commercial managed care population in clinical practice. Clin Ther. 2016 Sep;38(9):2046-2057. doi: 10.1016/j.clinthera.2016.07.009

Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy. Clin Ther. 2016 Jun;38(6):1376-91. doi: 10.1016/j.clinthera.2016.03.023

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021

Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.

Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013 Dec;35(12):1955-1963. doi: 10.1016/j.clinthera.2013.10.010

Davis AE, Mehrotra S, Friedewald J, Ladner D. Characteristics of a simulation model of the national kidney transplantation system. Poster presented at the 2013 Winter Simulation Conference: Simulation: Making Decisions in a Complex World; December 2013. [abstract] Ieee/Acm Trans Comput Biol Bioinform. 2013 Dec; p.2320-9.

Coon CD, McLeod LD. Patient-reported outcomes: current perspectives and future directions. Clin Ther. 2013 Apr 1;35(4):399-401.

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom. Clin Ther. 2012 Jul 1;34(7):1544-58.

Ferreira-Gonzalez I, Marsal JR, Ribera A, Permanyer-Miralda G, Garcia-Del Blanco B, Marti G, Cascant P, Martin-Yuste V, Brugaletta S, Sabate M, Alfonso F, Capote ML, De La Torre JM, Ruiz-Lera M, Sanmiguel D, Cardenas M, Pujol B, Baz JA, Iniguez A, Trillo R, Gonzalez-Bejar O, Casanova J, Sanchez-Gila J, Garcia-Dorado D. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation. 2010 Sep 7;122(10):1017-25. doi: 10.1161/CIRCULATIONAHA.110.938290

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009 Jan 1;31(1):194-212.

Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008 Feb;30(2):271-9. doi: 10.1016/j.clinthera.2008.02.005

Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther. 2007 Sep 1;29(9):2096-106.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug 1;28(8):1123-32.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in users of NSAIDs, including COX-2 selective inhibitors. A case/non-case analysis of spontaneous reports. Clin Ther. 2006;28(8):1123-32.

Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther. 2005 Mar;27(3):346-54. doi: 10.1016/S0149-2918(05)00052-4

Sapienza S, Sacco P, Floyd K, DiCesare J, Doan Q. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003 Jun;25(6):1872-87.

Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002 Jan 1;106(23):2919-24.

Adams MR, Golden DL, Register TC, Anthony MS, Hodgin JB, Williams JK. The atheroprotective effect to dietary soy isoflavones in apolipoprotein E -/- mice requires the presence of estrogen receptor-a. Circulation. 2002;p.106.

Carnethon MR, Anthony MS, Cascio WE, Folsom AR, Evans GE, Liao D. Prospective association between hormone replacement therapy and the QT index. Circulation. 2001;104:II-792.

Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000 Jun 6;101(22):2572-8.

Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.

Anthony MS, Clarkson TB, Evans GW. Estrogen-only versus estrogen + progestin replacement therapy: effects on coronary artery atherosclerosis extent and carotid artery intima-media thickness. Presented at the 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association; March 1, 2000. San Diego, CA. [abstract] Circulation. 2000; 101(6):714.

Williams K, Anthony MS, Andersen HL. A comparison of plant and mammalian estrogens on dilator and constrictor responses of atherosclerotic coronary arteries in postmenopausal monkeys. Circulation. 1998 Oct;98(Suppl I):I-463.

Clarkson TB, Anthony MS. Effect of hormone replacement therapy on internal carotid artery atherosclerosis on postmenopausal monkeys. Circulation. 1998;97:830.

Anthony MS, Clarkson TB. Comparison of soy phytoestrogens and conjugated equine estrogens on atherosclerosis progression on postmenopausal monkeys. Presented at the 38th Annual Conference on Cardiovascular Disease Epidemiology and Prevention; March 1998. Sante Fe, NM. [abstract] Circulation. 1998; 97:829.

Williams JK, Sukhova Gk, Anthony MS, Libby P. The cholesterol-lowering independent effects of pravastatin on the artery wall of monkeys. Circulation. 1997;96(Suppl I):I-607.

Anthony MS, Clarkson TB, Bullock BC. Soy protein versus soy phytoestrogens (isoflavones) in the prevention of coronary artery atherosclerosis of cynomolgus monkeys. Presented at the 69th Scientific Sessions of the American Heart Association; November 1996. New Orleans, LA. [abstract] Circulation. 1996; 94(Suppl I):I-265.

Moran CM, Fleming AD, Sutherland GR, Anderson T, McDicken WN. An evaluation of the properties of myocardial color Doppler energy mapping using test phantoms. Circulation. 1995 Oct 15;92(8):71.

Kaplan JR, Clarkson TB, Adams MR, Anthony MS, Manuck SB, Morgan TM. Oral contraceptives inhibit atherogenesis in female monkeys at high risk due to social subordination. Circulation. 1995;92(Suppl I):I-627.

Honoré EK, Williams JK, Anthony MS. Enhancement of coronary vasodilation by soy phytoestrogens. Circulation. 1995;92(Suppl I):I-349.

Anthony MS, Burke GL, Hughes CLJr, Clarkson TB. Does soy supplementation improve Coronary Heart Disease (CHD) risk? Presented at the 35th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association; March 1995. San Antonio, TX. [abstract] Circulation. 1995; 91:925.

Anthony MS, Clarkson TB, Hughes CL. Plant and mammalian estrogen effects on plasma lipids of female monkeys. Presented at the 67th Annual Scientific Sessions, American Heart Association; November 1994. Dallas, TX. [abstract] Circulation. 1994; 90:I-235.

Anthony MS, Crouse JR. Heterogeneity in plasma lipoprotein response to dietary fish oil. Presented at the 61st Scientific Sessions of the American Heart Association; November 1988. Washington, DC. [abstract] Circulation. 1988; 78(Suppl II):571. Previously presented at the 8th International Symposium on Atherosclerosis.